Investors have never been more bullish on Big Tech: Hedge fund total US net exposure to Magnificent 7 stocks is up to 22%, its highest on record. This figure has surged +7 percentage points since July, its largest 3-month increase since 2023. This is now above the 21% peak recorded in June 2024. By comparison, at the 2022 bear market low, net exposure to the Magnificent 7 was just 8%. Meanwhile, hedge fund total US net exposure to semiconductor stocks is up to 12%, just below the 14% peak recorded in June 2026. For perspective, this metric stood at just 2% at the start of 2025.

Nobody tells you how heavy it can get. One minute you’re up and feeling unstoppable. The next, a candle flips and you’re staring at the screen with a knot in your stomach, second-guessing every decision you made. The charts are the easy part. The hard part is managing your head while watching a green day turn red in minutes; Fighting the urge to revenge trade after a loss;Carrying a bad trade into dinner, into sleep, into the next days, weeks or months. Trading is one of the few things where you can do everything right and still lose, and that’s mentally exhausting. I handle it by stepping away for a few days and ensuring I do something totally unrelated to trading . I’m curious how the rest of you handle it: Do you step away from the screen like I do after a loss? Does exercise, meditation, or journaling help? What’s the one habit that keeps you level-headed? I would love to learn what works for you guys

We are about to witness one of the biggest disruptions in the history of the telecom and internet industry. Verizon stock, $VZ, falls -7% on news that SpaceX, $SPCX, is acquiring a spectrum license to become a major mobile carrier in the US. For decades, telecom and internet giants have dominated the industry with limited competition, slow innovation, and increasingly mediocre service. SpaceX, $SPCX, is about to change that. This is a clear wake up call to the current giants of the industry. Evolve or you will be left behind.

I think it deserves a thread. - "Zoetis Inc. has fallen 71% from its 2021 peak, now trading at 2017 levels, as pricing power eroded and pet medicine volumes declined. - Despite near-term headwinds, Zoetis maintains industry-leading margins and is positioned to weather price wars better than rivals due to its product mix and scale. - Patent expiries for Apoquel and Simparica in 2030/2032 are key risks, but a robust pipeline of 12 candidates could offset revenue losses if half succeed."

@Eric Seto thank you for MA PUT credit spread. I opened 4 contracts and collected $1.30 prem. I closed all of my positions and paid $0.17. Made good profit. Looking forward to next trade!